Innovation Delivered: Resco Launches Autumn Update at resco.next 2019 Keynote
24.10.2019 17:47:00 EEST | Business Wire | Press release
Resco, the leading provider of enterprise mobility solutions for Microsoft Dynamics 365 and Salesforce, has today officially introduced the Autumn Update 2019 at its annual resco.next conference in Rome.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191024005635/en/
Innovation delivered - Resco (Photo: Business Wire)
The release stands among Resco’s most significant, as it marks a year since the company officially began the expansion of its product portfolio with Resco Inspections, followed by Resco Routes. It delivers major new capabilities to both, as well as to the company’s Mobile Business Apps Platform.
“Our Autumn Update further strengthens Resco’s commitment to innovation that fosters business productivity. It also brings a number of features that extend Resco products to smartwatches,” confirmed Miro Pomsar, CEO at Resco.
More details in a fraction of time
With new Resco Inspections features like Tagged image and Reusable answers, field teams can complete inspections faster and provide more details with context to the back office. Ultimately, helping to speed up any issue resolution and boosting client satisfaction and loyalty.
Importantly, the solution is also coming to smartwatches as part of the Autumn Update. Field professionals can now complete inspection forms from their wrist, utilizing voice control for an entirely hands-free experience.
More information on Resco Inspections Autumn Update 2019 available here.
Handling unexpected situations
The upgraded Location Monitor in Resco Routes enables users to take the guesswork out of planning and effectively manage unforeseen events. Details such as an unlimited number of tracked staff members, real-time travel direction & speed, time of the last stop, and progress through the day, provide the backbone for truly informed decisions.
More information on Resco Routes Autumn Update 2019 available here.
Let the AI do the work
Resco’s Mobile Business Apps Platform has been extended with functionality that improves the efficiency of both mobile users and system administrators.
The all-new AI image recognition is available across all Resco-based app. Mobile users can now utilize image recognition instead of search or barcode scanning. More complex scenarios are also possible when utilizing image recognition in form rules.
Furthermore, when using Resco Cloud as a backend, administrators can create new fields and entities on the system directly from Woodford – no need to switch between applications. And with new project item categories, they can bring structure and clarity even to complex mobile projects.
More information on Resco’s Mobile Business Apps Platform Autumn Update 2019 available here.
Industry Watch for deeper business insights
At resco.next the company also introduced its all-new Industry Watch initiative - a new concept of utilizing smartwatches to obtain more insights from staff outdoors and indoors. Making entire organizations smarter and more efficient.
“We are excited about this new venture and the road that lies ahead. In the following months, we’re going to continue our intensive research in the area of wearables. We would also like to engage our whole ecosystem into this initiative, including our partners.” Miro Pomsar explained.
More details regarding Resco’s new smartwatch initiative can be found here.
About Resco
Resco founded in 1999, is one of the global leaders in developing cross-platform mobile software solutions. The team of Resco professionals utilizes their knowledge to design products for corporate customers, developers, integrators, and end users. Today, Resco is utilized by 2,800+ corporate customers with more than 250,000 licensed users around the world. The cornerstone of Resco’s Mobile Business Apps Platform is the Woodford configuration and management tool, which together with the Resco mobile app form the base of all Resco products.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191024005635/en/
Contact information
Resco Media Relations
Robert Feldmar
+421 2 209 020 17
communications@resco.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom